Flag­ship start­up All­tr­na rais­es $109M for tR­NA ther­a­pies that re­store miss­ing pro­teins

All­tr­na, a start­up found­ed by Flag­ship Pi­o­neer­ing, has raised $109 mil­lion in Se­ries B fi­nanc­ing to de­vel­op a new class of ge­net­ic med­i­cines based on trans­fer RNA mol­e­cules. It’s the largest round of fund­ing yet for a com­pa­ny fo­cused on ush­er­ing in an emerg­ing class of ge­net­ic ther­a­pies that promis­es to over­ride dis­ease-caus­ing mu­ta­tions.

Al­though tR­NA is well-known to bi­ol­o­gists for its vi­tal role in trans­lat­ing the mes­sen­ger RNA code in­to pro­teins, the mol­e­cules have re­ceived lit­tle at­ten­tion from biotech com­pa­nies un­til rel­a­tive­ly re­cent­ly. All­tr­na, hC Bio­science and Tevard Bio­sciences are among star­tups tin­ker­ing with tR­NA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER